- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00163982
Vasoactive Peptides in Portal Pressure
July 25, 2007 updated by: Bayside Health
This study is looking at the detection of vasoactive peptides in portal hypertension.
Study Overview
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: William W Kemp, MBBS, FRACP
- Phone Number: 3327 92762000
- Email: w.kemp@alfred.org.au
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3181
- Recruiting
- Alfred Hospital
-
Contact:
- William W Kemp, MBBS, FRACP
- Phone Number: 3327 92762000
- Email: w.kemp@alfred.org.au
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HVPG >= 12 mmHg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: William W Kemp, MBBS, FRACP, The Alfred
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 14, 2005
Study Record Updates
Last Update Posted (Estimate)
July 26, 2007
Last Update Submitted That Met QC Criteria
July 25, 2007
Last Verified
September 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Diseases
- Hypertension, Portal
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Norfloxacin
Other Study ID Numbers
- AH4204
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Portal Hypertension
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingIntrahepatic Non Cirrhotic Portal HypertensionFrance
-
Centro Hospitalar De São João, E.P.E.CompletedClinically Significant Portal HypertensionPortugal
-
University Hospital, ToursCompletedCirrhotic Portal HypertensionFrance
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPortal Hypertension | Clinically Significant Portal HypertensionUnited States
-
University Hospital, GhentCompletedEvaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.Liver Transplant With Clinically Significant Portal HypertensionBelgium
-
Universidade Federal do Rio de JaneiroNot yet recruitingPortal Hypertension | Idiopathic Non-Cirrhotic Portal Hypertension | Non-Cirrhotic Portal Hypertension | Vascular Disorder of Liver | Non-Cirrhotic Portal Fibrosis | Regenerative Nodular Hyperplasia | Incomplete Septal Cirrhosis | Obliterative Portal Venopathy | Hepatoportal Sclerosis | Idiopathic Portal...Brazil
-
Ain Shams UniversityCompleted
-
Assiut UniversityUnknownPredicting Liver Cell Failure & Portal Hypertension in LCEgypt
-
University Hospital, BonnCompleted
-
Tanta UniversityCompleted
Clinical Trials on Norfloxacin
-
Govind Ballabh Pant HospitalJhaver Research Foundation LimitedCompleted
-
Hospital Clinic of BarcelonaCompletedCirrhosis | Hepatorenal Syndrome | Spontaneous Bacterial PeritonitisSpain
-
All India Institute of Medical Sciences, New DelhiUnknownLiver Cirrhosis | Spontaneous Bacterial PeritonitisIndia
-
Postgraduate Institute of Medical Education and...Completed
-
Govind Ballabh Pant HospitalUnknown
-
Overseas Pharmaceuticals, Ltd.Guangzhou Health Start Pharmaceutical Techology Co.,LtdNot yet recruiting
-
Tanta UniversityRecruitingSpontaneous Bacterial PeritonitisEgypt
-
Unity Health TorontoUniversity of TorontoCompleted
-
Eurofarma Laboratorios S.A.Withdrawn